Andrew Coveler adds cancer immunotherapy, translational research expertise to Clinical Research Division
April 9, 2012
| By Colleen Steelquist
Dr. Andrew Coveler has joined the Fred Hutchinson Cancer Research Center's Clinical Research Division faculty. His research encompasses early phase clinical trials of new cancer drugs and immune-based treatments like vaccines and antibodies.
Course will aid participants’ preparation for the medical oncology certification or recertification exam and increase proficiency in management of patients with malignant disorders
July 5, 2011
The Seattle Cancer Care Alliance, in conjunction with the Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, will offer “Comprehensive Oncology Review,” an intensive, four-day continuing education course, Sept. 17-20, at W Hotel, 1112 Fourth Avenue in Seattle.
Case is first to show safety and effectiveness of using infection-fighting T cells alone to put late-stage melanoma into long-term remission
June 23, 2008
| By Dean Forbes
Scientists from Fred Hutchinson Cancer Research Center describe the first successful use of a human patient’s cloned infection-fighting T-cells as the sole therapy to put an advanced solid-tumor cancer into long-term remission
Life Sciences Discovery Fund grant will support phase 1 clinical-trials program to test novel therapies for solid tumors
April 21, 2008
| By Dean Forbes
The state's Life Sciences Discovery Fund has awarded $2.2 million to establish a formal phase 1 clinical-trials program to test new therapies for solid tumors through a collaborative effort of the Hutchinson Center and the University of Washington.
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.